ReviewDrugs2016
What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- A systematic review of qualitative research exploring patient and health professional perspectives of breakthrough cancer pain.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Pooled it
- A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.Cancer reports (Hoboken, N.J.) · 2019Trial
- Definition and Assessment of Paediatric Breakthrough Pain: A Qualitative Interview Study.Children (Basel, Switzerland) · 2024Article
- Compliance with the breakthrough cancer pain European guidelines and impact on patients' quality of life: an observational prospective study.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Breakthrough pain among cancer patients at oncology units in Northern Ethiopia; a multi-center study.Frontiers in oncology · 2023Article
- Fentanyl in cancer pain management: avoiding hasty judgments and discerning its potential benefits.Drugs in context · 2023Review
- Current management of cancer pain in Italy: Expert opinion paper.Open medicine (Warsaw, Poland) · 2022Review
- Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Breakthrough cancer pain: review and calls to action to improve its management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- The Roles of Battlefield Acupuncture and Electroacupuncture in a Patient with Cancer-Related Pain.Medical acupuncture · 2020Article
- Article
- Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain.Journal of pain research · 2019Article
- Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm.BMC palliative care · 2018Article
- Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.PloS one · 2017Article
- Article
- Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
26 authors at 15 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical management of breakthrough cancer pain (BTcP) is still not satisfactory despite the availability of effective pharmacological agents. This is in part linked to the lack of clarity regarding certain essential aspects of BTcP, including terminology, definition, epidemiology and assessment. Other barriers to effective management include a widespread prejudice among doctors and patients concerning the use of opioids, and inadequate assessment of pain severity, resulting in the prescription of ineffective drugs or doses. This review presents an overview of the appropriate and inappropriate actions to take in the diagnosis and treatment of BTcP, as determined by a panel of experts in the field. The ultimate aim is to provide a practical contribution to the unresolved issues in the management of BTcP. Five 'things to do' and five 'things not to do' in the diagnosis and treatment of BTcP are proposed, and evidence supporting said recommendations are described. It is the duty of all healthcare workers involved in managing cancer patients to be mindful of the possibility of BTcP occurrence and not to underestimate its severity. It is vital that all the necessary steps are carried out to establish an accurate and timely diagnosis, principally by establishing effective communication with the patient, the main information source. It is crucial that BTcP is treated with an effective pharmacological regimen and drug(s), dose and administration route prescribed are designed to suit the particular type of pain and importantly the individual needs of the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.